NIPD Genetics launches Oreana, a neonatal genetic screening test of 106 manageable genetic diseases that can affect normal development of children
January 25, 2021, Nicosia, Cyprus: NIPD Genetics announces the launch of Oreana, an expanded neonatal genetic screening test for newborns, infants or children, that screens for 106 genetic conditions in 142 genes. When detected early, the conditions tested in Oreana can be manageable or treatable given how therapies and clinical management can prevent serious, life-long consequences including developmental delay and premature death, benefiting the prognosis and the quality of life of the affected child.
Oreana neonatal genetic screening is for:
(a) Asymptomatic newborns or infants, for early identification of conditions which may not cause any symptoms initially and babies may not show any signs of illness. However, once symptoms begin, their damage may be irreparable and the health of the infant can deteriorate quickly, so early detection and interventions are beneficial for the infant.
(b) Symptomatic newborns, infantsor young children which have signs or symptoms of disease that can be difficult to be clearly identified due to complexity or variability of symptoms. In these cases, Oreana can correctly detect the genetic change (mutation) responsible for the disease and can point to the optimal treatment.
Oreana is built on NIPD Genetics’s proprietary and patented technology platform that has been validated in several studies and is trusted for its accuracy and precision. It screens for all coding regions on the genes tested, examining single nucleotide variants, small insertions and deletions and copy number variants. Oreana screens for Autosomal Recessive, Autosomal Dominant and X-Linked disorders of metabolic, endocrine, haemoglobin, pulmonary and musculoskeletal nature, as well as hearing loss and immunodeficiency disorders. The selection of the genetic conditions included in Oreana was based on the ‘Recommended Uniform Screening Panel’, which is a list of disorders selected based upon the American College of Medical Genetics (ACMG) recommendations for newborn screening.
NIPD Genetics’s Founder and CEO, Prof. Philippos Patsalis, stated on the launch of Oreana ‘Oreana neonatal genetic screening tests for 106 genetic disorders that are treatable or manageable. Early detection of infants who are affected by one of the diseases tested can significantly improve their life quality and prognosis. Oreana can complement national screening programs in screening asymptomatic infants, or be used to identify the genetic change responsible for causing clinical signs in symptomatic children. Early detection can prevent or minimize symptoms, limit irreparable health damage, avoid a lengthy or late diagnosis and enable informed decisions regarding early clinical management and interventions, benefiting the quality of life of affected infants’.
Oreana is performed through a simple, painless and non-invasive buccal swab. The sample is sent from the healthcare provider to NIPD Genetics’ central laboratory for analysis. Results are reported back to the healthcare provider within 2-3 weeks from sample receipt to the laboratory, allowing them to take informed and early decisions on the best clinical management for the infant and their families.
About NIPD Genetics:
NIPD Genetics is a leading, innovative biotechnology company that designs, develops and provides a broad spectrum of healthcare services through its expansive portfolio of molecular and clinical laboratory tests in all disciplines. Established in 2010, NIPD Genetics’s state-of-the-art laboratories are CAP-accredited and certified per CLIA and ISO standards. NIPD Genetics is committed to using its extensive know-how and advanced technology to safely, quickly and efficiently provide accurate and reliable results to our patients and partners throughout the world.
NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.
You may contact NIPD Genetics Public Company Ltd at NIPD Genetics Public Company Ltd Neas Engomis 31 Engomi, Nicosia 2409, Cyprus
NIPD Genetics Data Protection Officer can be reached at firstname.lastname@example.org
Type of personal information NIPD Genetics may collect through its Sites
The ways by which NIPD Genetics collects, uses or shares such information
Steps NIPD Genetics takes to protect its sites’ users personal information
This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.
Type of personal information NIPD Genetics may collect through its Sites
Information Collection And Use
We collect several different types of information for various purposes to provide and improve our Sites and services to you.
While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:
First name and last name
Address, State, Province, ZIP/Postal code, City
If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.
Cookies and Usage Data
We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
Tracking & Cookies Data
Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.
Examples of Cookies we use:
Session Cookies. We use Session Cookies to operate our Sites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the Sites
Keyword cookies. To understand how visitors discover the Sites.
Use of Data
www.nipd.com uses the collected data for various purposes:
To provide and maintain the Sites
To notify you about changes to our Sites
To allow you to participate in interactive features of our Sites when you choose to do so
To provide customer care and support
To provide analysis or valuable information so that we can improve the Sites
To monitor the usage of the Sites
To detect, prevent and address technical issues
Transfer of Data
Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
Disclosure of Data
NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.
NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:
To comply with a legal obligation
To protect and defend the rights or property of www.nipd.com
To prevent or investigate possible wrongdoing in connection with the Sites
To protect the personal safety of users of the Sites or the public
To protect against legal liability
Security of Data
The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.
We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
We may use third-party Service Providers to monitor and analyze the use of our Sites.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
Access to your personal data, correction, deletion, and Opting Out
You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer email@example.com
Links to Other Sites
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
Our Service does not address anyone under the age of 18 ("Children").
We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.